Risk factors

Five Below operates 1,771 stores with plans to exceed 3,500 locations, driving heavy reliance on new store openings, logistics network expansion, and inventory management.

First United faces heavy geographic concentration in Maryland and West Virginia real estate lending. Funding relies on customer deposits, FHLB advances, and brokered funds. Operations are subject to extensive banking regulation by the FRB, FDIC, and state agencies.

Washington D.C. area bank exposed to commercial real estate concentration and regional economic downturns. Heavy reliance on government contractor borrowers for commercial and industrial loans. Vulnerable to interest rate fluctuations, inflation, and deposit retention pressures.

Portfolio has significant tenant concentration with 30.6% in restaurants and 67% non-investment grade or unrated credit. Experienced net losses of $31.2 million in 2024 with a weighted average remaining lease term of 7.2 years. Growth strategy relies heavily on acquisitions, having acquired over $889.5 million of net-leased real estate since inception in 2016.

Monte Rosa faces early-stage biotech risks centered on its QuEENTM discovery engine and pipeline candidates like MRT-2359 and MRT-6160. The company lacks commercial product revenue, has a history of operating losses, and relies heavily on sole-source suppliers and third-party contractors.

Immunereing faces going concern doubts and needs substantial capital to fund its clinical-stage oncology pipeline. The company relies heavily on its unproven DCT platform and MAPK pathway targeting therapies like IMM-1-104 and IMM-6-415. Operations carry high regulatory, manufacturing, and third-party dependency risks without any commercialized products to date.

Substantially all assets consist of receivables from related parties, concentrating collection risk on affiliated real estate operations.

Invivyd faces going concern doubts, relying heavily on PEMGARDA's commercial success for revenue and profitability. The company has incurred substantial net losses, reaching $169.9 million in 2024. Operations are heavily dependent on third-party manufacturers like WuXi Biologics and compliance with FDA regulations.

Retail inventory management and consumer demand shifts dominate risk factors.

MacroGenics faces significant ongoing financial losses with an accumulated deficit of approximately $1.2 billion and a critical need for substantial additional funding. The company relies heavily on clinical trials for multiple product candidates and key development and commercialization collaborations. Operations are subject to extensive regulatory oversight, intellectual property challenges, and strict healthcare laws.

Mangoceuticals relies entirely on related-party pharmacy Epiq Scripts, controlled by its CEO, to compound its unapproved pharmaceutical products. The company faces a going concern risk, intense competition, and extensive regulation of telehealth and compounding.

Motorsport Games faces severe going concern doubts with a $91.8M accumulated deficit and $0.9M in cash.